Cellular mechanisms of serotonin 5-HT2A receptor-mediated cGMP formation: The essential role of glutamate

Brain Research

Volumn 1003, Issue 1-2, 2004, Pages 168-175

  Regina, Meredith J ^a   Bucelli, Robert C ^a   Winter, Jerrold C ^a   Rabin, Richard A ^a  

^a UNIVERSITY AT BUFFALO   (United States)

Author keywords

5 HT2A receptor; cGMP1; DOM; Frontal cortex; Glutamate; Interactions between neurotransmitters; Neurotransmitters, modulators, transporters, and receptors; NMDA receptor

Indexed keywords

2 AMINO 7 PHOSPHONOHEPTANOIC ACID; 2,5 DIMETHOXY 4 METHYLAMPHETAMINE; 6 CYANO 7 NITRO 2,3 QUINOXALINEDIONE; AMPA RECEPTOR ANTAGONIST; CYCLIC GMP; GLUTAMIC ACID; N METHYL DEXTRO ASPARTIC ACID RECEPTOR BLOCKING AGENT; SEROTONIN 2A AGONIST; SEROTONIN 2A RECEPTOR; TETANUS TOXIN;

ANIMAL TISSUE; ARTICLE; BRAIN SLICE; DRUG EFFECT; FRONTAL CORTEX; MALE; MEMBRANE VESICLE; NEUROTRANSMITTER RELEASE; NONHUMAN; PHEOCHROMOCYTOMA CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT;

ANIMALS; BRAIN; CYCLIC GMP; GLUTAMIC ACID; MALE; N-METHYLASPARTATE; PC12 CELLS; RATS; RATS, INBRED F344; RECEPTOR, SEROTONIN, 5-HT2A; RECEPTORS, N-METHYL-D-ASPARTATE; SEROTONIN AGONISTS;

EID: 1542268900     PISSN: 00068993     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.brainres.2004.01.014     Document Type: Article

References (39)

1. Aghajanian G., Marek G. Serotonin induces excitatory postynaptic potenials in apical dendrites of neocortical pyramidal cells. Neuropharmacology. 36:1997;589-599.
2. 2A receptors, increases EPSC's in layer V pyramidal cells of prefrontal cortex by an asynchronous mode of glutamate release. Brain Res. 825:1999;161-171.
3. Ali C., Salter M. NMDA receptor regulation by src kinase signalling in excitatory synaptic transmission and plasticity. Curr. Opin. Neurobiol. 11:2001;336-342.
4. 2A, 2C receptor agonist DOB on NMDA-evoked responses in the rat medial prefrontal cortex. Eur. J. Neurosci. 11:1999;2917-2934.
5. 2A receptors to inhibit NMDA-receptor mediated transmission in the rat prefrontal cortex. Eur. J. Neurosci. 11:1999;3064-3072.
6. Bliss T., Collingridge G. A synaptic model of memory: long-term potentiation in the hippocampus. Nature. 361:1993;31-39.
7. Bouron A. Modulation of spontaneous quantal release of neurotransmitters in the hippocampus. Prog. Neurobiol. 63:2001;613-635.
8. Brooker G., Harper J., Terasaki W., Moylan R. Radioimmunoassay of cyclic AMP and cyclic GMP. Adv. Cycl. Nucleotide Res. 10:1979;1-33.
9. Buhot M.C., Martin S., Segu L. Role of serotonin in memory impairment. Ann. Med. 32:2000;210-221.
10. A receptors in schizophrenia: studies on the human dorsolateral prefrontal cortex. J. Neurochem. 72:1999;1593-1599.
11. Ellingrod V.L., Perry P.J., Lund B.C., Bever-Stille K., Fleming F., Holman T.L., Miller D. 5HT2A and 5HT2C receptor polymorphisms and predicting clinical response to olanzapine in schizophrenia. J. Clim. Psychopharmacol. 22:2002;622-624.
12. 2C receptors in the stimulus effects of hallucinogenic drugs I: antagonist correlation analysis. Psychopharmacology. 121:1995;347-356.
13. Garthwaite J. Glutamate, nitric oxide and cell-cell signalling in the nervous system. Trends Neurosci. 14:1991;6067.
14. Grant E., Guttman R., Seifert K., Lynch D. A region of the rat N-methyl-D-aspartate receptor 2A subunit that is sufficient for potentiation by phorbol esters. Neurosci. Lett. 310:2001;9-12.
15. Grosshans D., Browning M. Protein kinase C activation induces tyrosine phosphorylation of the NR2A and NR2B subunits of the NMDA receptor. J. Neurochem. 76:2001;737-744.
16. Harvey A. Presynaptic effects of toxins. Int. Rev. Neurobiol. 32:1990;201-239.
17. Howard B., Gundersen C. Effects and mechanisms of polypeptide neurotoxins that act presynaptically. Annu. Rev. Pharmacol. Toxicol. 20:1980;307-336.
18. Humeau Y., Doussau F., Grant N., Poulain B. How botulinum and tetanus neurotoxins block neurotransmitter release. Biochimie. 82:2000;427-446.
19. Kohr G., Seeberg P. Subtype-specific regulation of recombinant NMDA receptor-channels by protein tyrosine kinases of the src family. J. Physiol. 492:1996;445-452.
20. Lane H.Y., Chang Y.C., Chiu C.C., Chen M.L., Hsieh M.H., Chang W.H. Association of risperidone treatment response with a polymorphism in the 5-HT(2A) receptor gene. Am. J. Psychiatry. 159:2002;1593-1595.
21. Leonard A.S., Hell J.W. Cyclic AMP-dependent protein kinase and protein kinase C phosphorylated N-methyl-D-asaparte receptors at different sites. J. Biol. Chem. 272:1997;12107-12115.
22. MacDonald J., Kotecha S., Lu W., Jackson M. Convergence of PKC-dependent kinase signal cascades on NMDA receptors. Curr. Drug Targets. 2:2001;299-312.
23. 2+ of NMDA responses in spinal cord neurons. Nature. 309:1984;261-263.
24. 2A receptor activation. J. Neurosci. Res. 67:2002;399-405.
25. 2A pKi values. J. Pharmacol. Exp. Ther. 251:1989;238-246.
26. Nakane M., Mitchell J., Forstermann U., Murad F. Phosphorylation by calcium calmodulin-dependent protein kinase II and protein kinase C modulates the activity of nitric oxide synthase. Biochem. Biophys. Res. Commun. 180:1991;1396-1402.
27. Polesskaya O.O., Sokolov B.P. Differential expression of the "C" and "T" alleles of the 5-HT2A receptor gene in the temporal cortex of normal individuals and schizophrenics. J. Neurosci. Res. 67:2002;812-822.
28. 2A receptor-stimulated phosphoinositide hydrolysis in the stimulus effects of hallucinogens. Pharmacol. Biochem. Behav. 71:2001;1-9.
29. Raymond J., Mukhin Y., Gelasco A., Turner J., Collinsworth G., Gettys T., Grewal J., Garnovskaya M. Multiplicity of mechanisms of serotonin receptor signal transduction. Pharmacol. Ther. 92:2001;179-212.
30. 2A receptors: increasing cMP levels in rat frontal cortex. Neuropharmacology. 45:2003;1041-1049.
31. Rossetto O., Seveso M., Caccin P., Schiavo G., Montecucco C. Tetanus and botulinum neurotoxins: turning bad guys into good by research. Toxicon. 39:2001;27-41.
32. Scruggs J.L., Schmidt D., Deutch A.Y. The hallucinogen 1-[2,5-dimethoxy-4-iodophenyl]-2-aminopropane (DOI) increases cortical extracellular glutamate levels in rats. Neurosci. Lett. 346:2003;137-140.
33. Shibuki K., Okada D. Endogenous nitric oxide release required for long-term synaptic depression in the cerebellum. Nature. 349:1991;326-328.
34. Vollenweider F.X., Vollenweider-Scherpenhuyzen M.F.I., Bäbler A., Vogel H., Hell D. Psilocybin induces schizophrenia-like psychosis in humans via a serotonin-2 agonist action. NeuroReport. 9:1998;3897-3902.
35. 2+-independent reduction of N-methyl-D-aspartate channel activity by protein tyrosine phosphatase. Proc. Natl. Acad. Sci. 93:1996;1721-1725.
36. Wei J., Roy D., Leconte L., Barnstable C. Molecular and pharmacological analysis of cyclic nucleotide-gated channel function in the central nervous system. Prog. Neurobiol. 56:1998;37-64.
37. Wei J.Y., Jin X., Cohen E.D., Daw N.W., Barnstable C.J. cGMP-induced presynaptic depression and postsynaptic facilitation at glutamatergic synapses in the visual cortex. Brain Res. 927:2002;42-54.
38. Xiong Z.G., Raouf R., Lu W.Y., Orser B.A., Dudek E.M., Browning M.D., MacDonald J.F. Regulation of N-methyl-D-aspartate receptor function by constitutively active protein kinase C. Mol. Pharmacol. 54:1998;1055-1063.
39. Zwiller J., Revel M.O., Malviya A. Protein kinase C catalyzes phosphorylation of guanylate cyclase in vitro. J. Biol. Chem. 260:1985;1350-1353.